GLOSSARY

GLOSSARY

Title Content
Agriculture Act of 2014 Known as the "Farm Bill,", this was signed by President Obama on February 7, 2014. Section 7606 highlights the "Legitimacy of Industrial Hemp Research," authorizing industrail hemp (Cannabis plants containing 0.3% or less THC by weight) to be used in research and pilot programs by institutions of higher education or State6
  • Vitamins
  • Amino Acids
  • Metabolites
  • Substances to increase total dietary intake
  • Minerals
  • Concentrates
  • Herbs or Other Botanicals
Cannbinoids 2
Cannabis 3
Cannabis Oil* 4
Cannabis Sativa L. 5
CBD Oil*/Hemp CBD Oil* 6
CBD-Rich Extracts* 7
DEA-Drug Scheduling 8
Dietary Supplement 9
Endocannabinoids 10
Endocannabinoids Receptors 11
Endocannabinoids Systems 12
Entourage Effect* 13
FDA-Approved Formulation of CBD* 14
FDA-Approved Medication 15
Hemp 16
Hemp Oil*/Hempseed Oil 17
Marijuana 18
Medical Marijuana (MM)* 19
Nutraceutical* 20
Phytocannabinoids 21
Recreational Marijuana (RM)* 22
Synthetic Cannabinoids 23
Terpenes/Terpenoids 24
Whole Plant 25

Cannabis sativa L. is a genius jof flowering plants in the Cannabaceae family1

It has been used therapeutically for thousands of years, while also being notorious for its "high"-inducing psychotrapic effects.2 But now with the discovery of cannabinoids, we are able to better understand the cause of these effects.

Let's begin by breaking down these cannabinoids into 3 main classes: endocannabinoids, phytocannabinoids, and synthetic cannabinoids.

endocannabinoid

Endocannabinoids

endocannabinoid

Phytocannabinoids

endocannabinoid

Synthetic Cannabinoids

Test your knowledge

THC and CBD are 2 different cannabinoids that both cause the high that is commonly associated with marijuana.23-25

That is common misconception.

Actually, CBD is a cannabinoid lacking euphoric side effects.2,6

Find Out More

You're right!

CBD is a cannabinoid lacking euphoric side effects.2,6

Find Out More
  • 1. Grotenherman F. Cannabinoids and the endocannabinoid system. Cannabinoids. 2006;1(1):10-14.
  • 2. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Brit J Pharmacol. 2006;147(Suppl 1):S163-S171.
  • 3. Ramer R, Schwarz R, Hinz B. Modulation of the endocannabinoid system as a potential anticancer strategy. Front Pharmacol. 2019;10:1-17.
  • 4. Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19(3):1-23.
  • 5. Maccarrone M, Bab I, Biro T, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci. 2015;36(5):277-296.
  • 6. EPIDIOLEX [package insert]. Carlsbad, CA: Greenwich Biosciences, Inc.; 2018.
  • 7. FDA News Release: FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms. Accessed August 20, 2019.
  • 8. United States Department of Agriculture. Agricultural Marketing Service. https://www.ams.usda.gov/sites/default/files/media/2018FarmBill.pdf. Accessed August 20, 2019.
  • 9. Ibeas Bih C, Chen T, Nunn AVW, Bazelot M, Dallas M, Whalley BJ. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015;12(4):699-730.
  • 10. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017;318(17):1708-1709.
  • 11. Vandrey R, Raber JC, Raber ME, et al. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA. 2015;313(24):2491-2493.
  • 12. FDA Warning Letters and Test Results for Cannabidiol-Related Products 2015 to 2019. https://www.fda.gov/news-events/public-health-focus/warning-letters-and-test-results-cannabidiol-related-products. Accessed August 20, 2019.
  • 13. Marinol [package insert]. North Chicago, IL: AbbVie Inc; 2017.
  • 14. Cesamet [package insert]. Somerset, NJ: Meda Pharmaceuticals Inc; 2015.
  • 15. Syndros [package insert]. Chandler, AZ: Insys Therapeutics, Inc; 2017.
  • 16. Ruthirakuhan M, Herrmann N, Gallagher D, et al. Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: study protocol for a cross-over randomized controlled trial. Contemp Clin Trials Commun. 2019;15:1-7.
  • 17. Peball M, Werkmann M, Ellmerer P, et al. Nabilone for non‑motor symptoms of Parkinson’s disease: a randomized placebo‑controlled, double‑blind, parallel‑group, enriched enrolment randomized withdrawal study (The NMS‑Nab Study). J Neural Transm (Vienna). 2019;126(8):1061-1072.
  • 18. Mascal M, Hafezi N, Wang D, et al. Synthetic, non-intoxicating 8,9-dihydrocannabidiol for the mitigation of seizures. Sci Rep. 2019;9(1):1-6.
  • 19. National Institutes of Health. Search results: synthetic cannabinoids. https://clinicaltrials.gov/ct2/show/NCT04001010. Accessed August 20, 2019.
  • 20. National Institutes of Health. Search results: dronabinol. https://clinicaltrials.gov/ct2/results. Accessed August 20, 2019.
  • 21. National Institutes of Health. Search results: nabilone. https://clinicaltrials.gov/ct2/results. Accessed August 20, 2019.